An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer
- 28 May 2015
- journal article
- case report
- Published by Springer Science and Business Media LLC in Journal of Gastrointestinal Cancer
- Vol. 47 (2), 206-209
- https://doi.org/10.1007/s12029-015-9735-y
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- The prognostic value of KRAS mutations in patients with colorectal cancerOncology Reports, 2012
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEuropean Journal of Cancer, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysisClinical Colorectal Cancer, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialJournal of Clinical Oncology, 2010
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- Clinicopathological features of CpG island methylator phenotype‐positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutationPathology International, 2008
- Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.2000
- Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.1998